Payer perspective on new data for an oncology product (US, UK, Italy, Germany and Brazil)
Our client was a Pricing & Market Access Director in a top 5 European-based company with significant success in the oncology field. Clinical data were emerging for a new dose of the product in breast cancer and they wanted to understand the likely reception by their affiliates and their payer customers to the new evidence.
The client challenge
Our client needed both an external expert view and payer perspective on the new data in each market in order to make recommendations on how to augment the existing value evidence base.
How we helped
We took the existing value proposition and evidence to affiliates in UK, Italy, Germany, US and Brazil and held workshops with each of them to define the local issues that affected the uptake of the product. We also defined the affiliate perspective on the pricing and access issues for the new clinical data and value proposition. Following this, we talked to payers and those influencing access in each market to get their reactions to the likely price proposals and value arguments for the new dose.
Our recommendations described the likely payer acceptance of different price levels, contingent upon different clinical and economic evidence scenarios. Our client was very pleased with the insights we delivered and the depth of our thinking and research. The recommendations were included in presentations to the senior commercial review group.